The news: Novo Nordisk and Amazon Web Services (AWS) are partnering to accelerate drug discovery and modernize Novo’s operations using agentic AI and cloud technology. The duo is creating a co-innovation hub in London where AWS engineers and Novo research teams will identify drug targets, design therapies, and shorten the path from target discovery to first human dose.

Why it matters: Large drugmakers are pairing their biological data, clinical expertise, and development infrastructure with the computational platforms and engineering talent of tech companies to speed up drug discovery and build out AI capabilities. Novartis CEO Vas Narasimhan recently said AI could cut drug development timelines from roughly 12 years to seven or eight, while potentially doubling the industry’s clinical trial-to-FDA-approval success rate from about 8% to 16%. Recent tie-ups follow the same pattern, including Merck with Google Cloud, Takeda with Iambic, and Eli Lilly with Insilico, and multiple partnerships between OpenAI and Nvidia and drugmakers.

Novo is spreading commitments across several AI partners. It signed a deal worth up to $812 million with Deep Apple Therapeutics to discover non-incretin cardiometabolic drugs, and it holds separate arrangements with OpenAI, Nvidia, and H1. This approach gives a well-funded drugmaker exposure to different models, datasets, and approaches, with the flexibility to prioritize those most likely to boost R&D productivity and accelerate time to market.

Implications for pharma and tech companies: The Novo-AWS deal signals a significant and growing opportunity for tech players and AI vendors to embed themselves more deeply into drug development workflows. Anthropic's recent move to launch a dedicated Claude Science platform for pharma researchers reflects the supply side of that trend: AI specialists are positioning themselves as integrated infrastructure providers for life sciences R&D.

This dynamic favors companies with the balance sheets to pursue multiple AI partnerships in parallel. Smaller pharma and biotech firms may struggle to afford leading platforms, negotiate favorable terms, or attract the most sought-after AI partners—particularly as large drugmakers build portfolios of strategic AI relationships.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.